Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Assembly Biosciences Inc (NASDAQ:ASMB)

14.97
Delayed Data
As of Aug 03
 -0.03 / -0.20%
Today’s Change
5.91
Today|||52-Week Range
20.50
+90.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$257.7M

Company Description

Assembly Biosciences, Inc. operates as a biopharmaceutical company which develops novel treatments for hepatitis B virus infection and C. difficile-associated diarrhea. It specializes in the development of therapies for infectious diseases like HIV, CDAD and other disorders of the gastrointestinal system including of late-stage and pre-clinical prescription drugs and biologics. The company was founded on October 7, 2005 and is headquartered in New York, NY.

Contact Information

Assembly Biosciences, Inc.
99 Hudson Street
New York New York 10013
P:(646) 706-5208
Investor Relations:

Employees

Shareholders

Other institutional46.54%
Mutual fund holders16.66%
Individual stakeholders13.41%

Top Executives

Derek A. SmallPresident, Chief Executive Officer & Director
David J. BarrettSecretary, Chief Operating & Financial Officer
Uri A. LopatinChief Medical Officer & Vice President
Lee D. ArnoldChief Scientific Officer
J. P. BenyaVice President-Business Development